EligibleTrials

Clinical trials recruiting for CCNE1 Amplification

3
Recruiting trials
22
US states with sites
2
Countries
0%
Accept healthy volunteers

Phase breakdown

Phase 1 3Phase 2 2

Drugs and treatments being studied

InterventionTrials
Abemaciclib2
Fulvestrant2
AVZO-0211
Carboplatin1
INX-3151
Letrozole1
NKT39641
Palbociclib1
Ribociclib1
Sacituzumab Govitecan-hziy1

Where trials are recruiting (top US states)

StateRecruiting trials
Florida3
Texas3
Georgia2
Massachusetts2
New York2
Ohio2
Pennsylvania2
Virginia2
Arkansas1
California1
Colorado1
Connecticut1

Top cities

Dallas, Texas 3Atlanta, Georgia 2Augusta, Georgia 2Boston, Massachusetts 2Fairfax, Virginia 2Orlando, Florida 2Philadelphia, Pennsylvania 2Austin, Texas 1Buffalo, New York 1Canton, Ohio 1

Self-screener

Recruiting trials

Related conditions

Trials recruiting for CCNE1 Amplification often also study these conditions. Each links to its own recruiting-trial list.

Breast cancer 2239Ovarian cancer 118Human Epidermal Growth Factor 2 Negative Carcinoma of Breast 4Triple Negative Breast Neoplasms 12Triple-negative breast cancer 138TNBC - Triple-Negative Breast Cancer 35Solid Tumor, Adult 38Small Cell Lung Carcinoma 20Small cell lung cancer 87Primary Peritoneal Cancer 6

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for CCNE1 Amplification trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.